European Commission Targets Teva Over Alleged Copaxone Antitrust Breach
Teva Prepared To Use All Legal And Procedural Rights Available
Executive Summary
A European Commission investigation into Teva’s conduct over its Copaxone multiple sclerosis drug has led to the firm receiving a statement of objections, which details a preliminary finding that the company violated EU antitrust laws.
You may also be interested in...
MSD Fined €39m In Spain Over Blocking Nuvaring Rival
Spanish competition regulator the CNMC has fined Merck Sharp and Dohme €39m for abusing its dominant position, by blocking Insud Pharma’s rival to the Nuvaring vaginal contraceptive ring through “unjustified legal action” that sought to delay market entry of Insud’s Ornibel version. The originator is considering an appeal.
Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.